Dynavax Technologies Corporation (DVAX)

NASDAQ: DVAX · Real-Time Price · USD
9.75
+0.25 (2.63%)
At close: May 29, 2025, 4:00 PM
9.84
+0.09 (0.92%)
After-hours: May 29, 2025, 5:45 PM EDT
2.63%
Market Cap 1.17B
Revenue (ttm) 294.62M
Net Income (ttm) -60.07M
Shares Out 120.08M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE 20.10
Dividend n/a
Ex-Dividend Date n/a
Volume 1,928,570
Open 9.51
Previous Close 9.50
Day's Range 9.51 - 9.85
52-Week Range 9.22 - 14.63
Beta 1.26
Analysts Buy
Price Target 26.25 (+169.23%)
Earnings Date May 6, 2025

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]

Sector Healthcare
IPO Date Feb 19, 2004
Employees 405
Stock Exchange NASDAQ
Ticker Symbol DVAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $26.25, which is an increase of 169.23% from the latest price.

Price Target
$26.25
(169.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...

1 day ago - PRNewsWire

Deep Track Capital Comments on ISS Recommendation

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...

6 days ago - Business Wire

ISS backs Dynavax directors in board fight with Deep Track Capital

Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Trac...

6 days ago - Reuters

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleadin...

6 days ago - PRNewsWire

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balance...

8 days ago - Seeking Alpha

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...

14 days ago - Business Wire

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EM...

17 days ago - PRNewsWire

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Fo...

22 days ago - PRNewsWire

Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript

Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ry...

23 days ago - Seeking Alpha

Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pande...

23 days ago - PRNewsWire

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dyn...

23 days ago - Business Wire

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Over half of American adults do not know chronic hepatitis B can cause liver disease such as cirrhosis and liver cancer Half of American adults were unaware that anyone can be at risk for the hepatiti...

4 weeks ago - PRNewsWire

Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy

Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card EMERYVILLE, Calif. , April 29, 2025 /PRNewswire/ -- Dynavax Technologies Corpor...

4 weeks ago - PRNewsWire

Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

EMERYVILLE, Calif. , April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wi...

5 weeks ago - PRNewsWire

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...

5 weeks ago - Business Wire

Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation Strategy andMeaningful Board...

6 weeks ago - PRNewsWire

Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“...

6 weeks ago - Business Wire

Dynavax Files Preliminary Proxy Statement

Dynavax's Board is Overseeing Record Operational and Financial Performance Outlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a Resolution EMERYVILLE, Calif. , April 3, 2025 ...

2 months ago - PRNewsWire

Deep Track Capital Sends Letter to Dynavax Technologies' Board of Directors

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...

2 months ago - Business Wire

Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase

Opportunistic refinancing extends the maturity of most of existing debt with improved terms and reduces dilution to existing capital structure $225 million of convertible notes due in 2030 issued, inc...

3 months ago - PRNewsWire

Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share

Dynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup...

3 months ago - Seeking Alpha

Dynavax to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...

3 months ago - PRNewsWire

Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript

Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati...

3 months ago - Seeking Alpha

Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in Phase 1/2 shingles trial expected in Q...

3 months ago - PRNewsWire

Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy

Reiterates Meaningful Board Change Already Underway EMERYVILLE, Calif. , Feb. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage ...

3 months ago - PRNewsWire